how do glp-1 receptor agonists work Current Insights, Advantages and Challenges of Small Molecule Glucagon-like Peptide 1 Agonists: A Scoping Review glp-1_analogs [TUSOM | Pharmwiki]

Lancet 2009;373:473481

Ten Kulve, J

"GI AEs typically occur during initiation and uptitration, appearing as transient, mild-to-moderate symptoms." Laura Schalliol, PharmD, BCACP, BCGP, Professor of Pharmacy Practice In fact, 94% of adverse events reported in major clinical trials were mild or moderate in severity

After 36 weeks, the 0.5 mg retatrutide group showed a 3.19% body weight reduction, the 4 mg group showed a 10.37% decrease, the 8 and 12 mg groups demonstrated decreases of 16.81% and 16.94% respectively, which were significantly greater than those observed with placebo (3.00%) and 1.5 mg dulaglutide (2.02%) [114]